BioXcel Therapeutics, Inc. (BTAI)
Confidential investigation: officers & directors’ potential breach of fiduciary duties to investors.
Investigation
11/23/2021
Initial Lawsuit
11/23/2021
Lawsuit Progression
03/09/2022
Investigation regarding statements made by Playtika in connection with its initial public offering (IPO) about its total Q3 2021 costs, sustainability of its game portfolio and subsequent negative impact on its operations.
11/03/2021
Playtika releases its Q3 2021 financial results with Q3 revenue of $635.9 million compared to $613.3 million in the prior year period and net income of $80.5 million compared to $119.9 million in the prior year period.
The company also disclosed sales and marketing costs and expenses for Q3 2021 of $141.1 million compared to $116.7 for Q3 2020. Total costs and expenses for Q3 2021 were at $481.4, or 17.53%, as compared to $409.6 for Q3 2020.
Stock Impact
Close | Previous close | Price variation | Percentage variation |
---|---|---|---|
$22.72 | $29.52 | $-6.8 | -23.04% |
Plaintiff brings this federal securities class action on behalf of a class consisting of all persons and entities other than defendants who purchased or otherwise acquired:
(a) Playtika securities pursuant and/or traceable to the company’s initial public offering conducted on or about January 15, 2021; or
(b) Playtika securities between January 15, 2021 and November 2, 2021, both dates inclusive.
According to the complaint, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects. Specifically, defendants allegedly failed to disclose to investors that:
(i) the company’s year-over-year total costs and costs related to sales & marketing and research & development were on track to rise significantly by the third quarter of 2021;
(ii) the success of the company’s game portfolio was less sustainable than the company had represented;
(iii) the foregoing issues were likely to negatively impact the company’s revenue and earnings; and
(iv) as a result, the company’s public statements were materially false and misleading at all relevant times.
03/09/2022
The court issued an order appointing the lead plaintiff and lead counsel.
05/06/2022
This securities action is brought on behalf of a class of all persons or entities who purchased or otherwise acquired Playtika common stock pursuant and/or traceable to the company’s registration statement, filed in connection with its January 15, 2021 initial public offering (IPO) of 79,925,000 shares of common stock at a price of $27.00.
Operative complaint
Confidential investigation: officers & directors’ potential breach of fiduciary duties to investors.